Complete Genomics Looks to Net $64M in Stock Offering, Plans to Expand Sequencing Capacity | GenomeWeb

This article was originally published May 26.

In order to expand its sequencing capacity, build up its sales and marketing team, and further develop its sequencing technology, Complete Genomics is offering 5.5 million shares of its common stock at $12.50 per share.

Additionally, it has offered its underwriters a 30-day option to purchase up to 825,000 additional shares at the public offering price, less the underwriting discounts and commissions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.